Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Requirement for monthly heparin testing updates canceled

This article was originally published in The Gold Sheet

Executive Summary

FDA in March stopped requiring heparin manufacturers to provide the agency monthly updates on heparin test results. Last year, FDA established screening methods involving capillary electrophoresis and proton nuclear magnetic resonance to identify and remove from the market heparin that had been adulterated with oversulfated chondroitin sulfate. The agency asked all manufacturers to perform the tests and provide it with monthly updates on their results. Although FDA is no longer requiring the updates, it reminded manufacturers to continue notifying it of any positive results within three days of testing. Noting that the U.S. Pharmacopeia has added the new testing methods to its heparin monograph, FDA said its inspection program will monitor adherence to the appropriate testing regimen

You may also be interested in...



Agios’ Mitapivat Shows Improvement In Regularly Transfused PKD Patients

While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.

Medtech Industry Favorite Wins Seat On Powerful House E&C Committee

As a freshman member on the US House Energy and Commerce Committee, former St. Jude Medical exec Rep. Angie Craig can help shape future health care, cybersecurity bills.

Source: 3 Former Obama US CMS Officials Being Considered To Lead Biden’s Medicare Agency

The three names under consideration also have a history of focusing on helping underprivileged communities get access to health care.

UsernamePublicRestriction

Register

OM013202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel